Zobrazeno 11 - 20
of 627
pro vyhledávání: ''
Publikováno v:
New England Journal of Medicine. 381:1493-1495
Autor:
Toni Sarapohja, M. Luz, Iris Kuss, Aramis Investigators, Christian Kappeler, Matthew R. Smith, Amir Snapir, Boris Alekseev, Neal D. Shore, Teuvo L.J. Tammela, Mindaugas Jievaltas, Sergey Polyakov, Albertas Ulys, Karim Fizazi, Egils Vjaters
Publikováno v:
New England Journal of Medicine. 380:1235-1246
Darolutamide is a structurally unique androgen-receptor antagonist that is under development for the treatment of prostate cancer. We evaluated the efficacy of darolutamide for delaying metastasis and death in men with nonmetastatic, castration-resis
Autor:
Kalehiwot M Wubie, Marcus V. G. Lacerda, Françoise Brand, Kim Fletcher, Alemseged Abdissa, Nillawan Buathong, Elizabeth Hardaker, Harald Noedl, Victoria M Rousell, Ermias Diro, Jörg-Peter Kleim, Monica R. F. Costa, Brian Angus, John J Breton, Alejandro Llanos-Cuentas, Lynda Kellam, Reginaldo Z Mia, Marcelo A M Brito, Martin Casapia, Hans-Peter Beck, Fe Espino, Raul Chuquiyauri, Wuelton Marcelo Monteiro, Rezika Mohammed, Donna D Clover, Fernando Val, Sisay Getie, Justin A. Green, Dhelio Batista Pereira, Daniel Yilma, Stephan Duparc, Mauro Shugiro Tada, Cherinet Abebe, Ahmed Zeynudin, Siôn W. Jones, Khadeeja Mohamed, David L. Saunders, Cletus O Ugwuegbulam, Gavin C. K. W. Koh, Chanthap Lon, Srivicha Krudsood
Publikováno v:
The New England Journal of Medicine
Background Treatment of Plasmodium vivax malaria requires the clearing of asexual parasites, but relapse can be prevented only if dormant hypnozoites are cleared from the liver (a treatment termed “radical cure”). Tafenoquine is a single-dose 8-a
Autor:
Kolb, Martin, Raghu, Ganesh, Wells, Athol U, Behr, Jürgen, Richeldi, Luca, Schinzel, Birgit, Quaresma, Manuel, Stowasser, Susanne, INSTAGE Trial Investigators, Benjamin Bondue, Bondue, Benjamin, Martinez, Fernando J
Publikováno v:
The New England journal of medicine, 379 (18
Background Nintedanib is an approved treatment for idiopathic pulmonary fibrosis (IPF). A subgroup analysis of a previously published trial suggested that sildenafil may provide benefits regarding oxygenation, gas exchange as measured by the diffusio
Autor:
Santos, Raul D., Ruzza, Andrea, Hovingh, G. Kees, Wiegman, Albert, Mach, François, Kurtz, Christopher E., Hamer, Andrew, Bridges, Ian, Bartuli, Andrea, Bergeron, Jean, Szamosi, Tamás, Santra, Saikat, Stefanutti, Claudia, Descamps, Olivier S., Greber-Platzer, Susanne, Luirink, Ilse, Kastelein, John J.P., Gaudet, Daniel, HAUSER-RCT INVESTIGATORS, Stéphenne, Xavier, Sokal, Etienne
Publikováno v:
New England Journal of Medicine, Vol. 383, no.14, p. 1317-1327 (2020)
New England journal of medicine, 383(14), 1317-1327. Massachussetts Medical Society
New England journal of medicine, 383(14), 1317-1327. Massachussetts Medical Society
Background: Evolocumab, a fully human monoclonal antibody directed against proprotein convertase subtilisin-kexin type 9, is widely used in adult patients to lower low-density lipoprotein (LDL) cholesterol levels. Its effects in pediatric patients wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f35e4feac7bc13735489d78b35e44247
https://hdl.handle.net/2078.1/239255
https://hdl.handle.net/2078.1/239255
Autor:
Goldman, Jason D., Lye, David C.B., Hui, David S., Marks, Kristen M., Bruno, Raffaele, Montejano, Rocio, Spinner, Christoph D., Galli, Massimo, Ahn, Mi‑Young, Nahass, Ronald G., Chen, Yao-Shen, SenGupta, Devi, Hyland, Robert H., Osinusi, Anu O., Cao, Huyen, Blair, Christiana, Wei, Xuelian, Gaggar, Anuj, Brainard, Diana M., Towner, William J., Muñoz Gutiérrez, José, Mullane, Kathleen M., Marty, Francisco M., Tashima, Karen T., Diaz, George, Subramanian, Aruna, GS-US-540-5773 Investigators
Publikováno v:
Dipòsit Digital de la UB
Universidad de Barcelona
New England Journal of Medicine
The New England Journal of Medicine
Universidad de Barcelona
New England Journal of Medicine
The New England Journal of Medicine
Background Remdesivir is an RNA polymerase inhibitor with potent antiviral activity in vitro and efficacy in animal models of coronavirus disease 2019 (Covid-19). Methods We conducted a randomized, open-label, phase 3 trial involving hospitalized pat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::149c6c167a6df7239d17494c5ec23e9d
http://hdl.handle.net/2445/174122
http://hdl.handle.net/2445/174122
Autor:
Lucie Blondeau, Mylène Provencher, Olivier F. Bertrand, Aldo P. Maggioni, José López-Sendón, Jean-Claude Tardif, François Roubille, Simon Kouz, Wolfgang Koenig, Marie-Pierre Dubé, Rafael Diaz, Andreas Orfanos, Reda Ibrahim, Denis Angoulvant, Petr Ostadal, Fausto J. Pinto, Jean Grégoire, Ghassan S. Kiwan, Marie-Claude Guertin, David D. Waters, Marc-André Lavoie, David Rhainds, Colin Berry, Habib Gamra, Philippe L. L’Allier
Publikováno v:
Repositório Científico de Acesso Aberto de Portugal
Repositório Científico de Acesso Aberto de Portugal (RCAAP)
instacron:RCAAP
New England Journal of Medicine
New England Journal of Medicine, 2019, ⟨10.1056/NEJMoa1912388⟩
The New England journal of medicine, vol 381, iss 26
New England Journal of Medicine, Massachusetts Medical Society, 2019, ⟨10.1056/NEJMoa1912388⟩
Repositório Científico de Acesso Aberto de Portugal (RCAAP)
instacron:RCAAP
New England Journal of Medicine
New England Journal of Medicine, 2019, ⟨10.1056/NEJMoa1912388⟩
The New England journal of medicine, vol 381, iss 26
New England Journal of Medicine, Massachusetts Medical Society, 2019, ⟨10.1056/NEJMoa1912388⟩
Copyright © 2019 Massachusetts Medical Society. All rights reserved.
Background: Experimental and clinical evidence support the role of inflammation in atherosclerosis and its complications. Colchicine is an orally administered, potent antiinfl
Background: Experimental and clinical evidence support the role of inflammation in atherosclerosis and its complications. Colchicine is an orally administered, potent antiinfl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::245444c6724cffe5dc69b81d63e21083
https://eprints.gla.ac.uk/204890/1/204890.pdf
https://eprints.gla.ac.uk/204890/1/204890.pdf
Autor:
Johannes Oldenburg, Víctor Jiménez-Yuste, Gallia G. Levy, M Elisa Mancuso, Willem Bujan, Christine L. Kempton, Elina Asikanius, Joanne I. Adamkewicz, Christophe Dhalluin, Markus Niggli, Midori Shima, Ido Paz-Priel, Michael U. Callaghan, Claude Negrier, Johnny Mahlangu, Christophe Schmitt, Rebecca Kruse-Jarres
Publikováno v:
New England Journal of Medicine. 379:811-822
Emicizumab is a bispecific monoclonal antibody that bridges activated factor IX and factor X to replace the function of missing activated factor VIII, thereby restoring hemostasis. In a phase 3, multicenter trial, we investigated its use as prophylax
Autor:
Morten Schou, Tzvetana Katova, Lars Køber, AM Langkilde, Béla Merkely, Chern-En Chiang, Pham Nguyen Vinh, Piotr Ponikowski, Jarosław Drożdż, Masafumi Kitakaze, Michael Böhm, Andrej Dukát, Kieran F. Docherty, Eileen O'Meara, Felipe Martinez, Rudolf A. de Boer, Mikaela Sjöstrand, Mirta Diez, Jose C. Nicolau, Tereshchenko Sn, Inder S. Anand, Vijay K. Chopra, Marc S. Sabatine, Akshay S. Desai, John J.V. McMurray, Junbo Ge, Pardeep S. Jhund, Mark C. Petrie, Silvio E. Inzucchi, Olof Bengtsson, Mikhail Kosiborod, Charlotta Ljungman, Claes Held, David L. DeMets, Jan Bělohlávek, Subodh Verma, Jonathan G. Howlett, Scott D. Solomon
Publikováno v:
New England Journal of Medicine, 381(21), 1995-2008. MASSACHUSETTS MEDICAL SOC
Background: \ud In patients with type 2 diabetes, inhibitors of sodium–glucose cotransporter 2 (SGLT2) reduce the risk of a first hospitalization for heart failure, possibly through glucose-independent mechanisms. More data are needed regarding the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3d69c6f3bca317ea7d269a51b0fcf4bc
https://eprints.gla.ac.uk/197128/1/197128.pdf
https://eprints.gla.ac.uk/197128/1/197128.pdf
Autor:
Maha Hussain, Karim Fizazi, Neal D. Shore, Andrew Krivoshik, Per Rathenborg, Katharina Modelska, De Phung, Ubirajara Ferreira, Fred Saad, Petro Ivashchenko, Eren Demirhan, Cora N. Sternberg
Publikováno v:
N Engl J Med
BACKGROUND: Men with nonmetastatic, castration-resistant prostate cancer and a rapidly rising prostate-specific antigen (PSA) level are at high risk for metastasis. We hypothesized that enzalutamide, which prolongs overall survival among patients wit